Plain-English translation of NCT06492421 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lung Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new way to treat early-stage non-small cell lung cancer by injecting two immune-boosting medications—ipilimumab and pembrolizumab (or durvalumab)—directly into the tumor before surgery. Researchers believe delivering these medications straight to the cancer may work better and cause fewer side effects than the standard approach of giving them through the vein. The trial will also test whether adding chemotherapy or other drugs improves results.
Current immune therapies for lung cancer are given through the bloodstream, which means lower concentrations reach the tumor itself. By injecting the medication directly into the cancer, doctors hope to increase how well it works while reducing side effects throughout the body.
You likely qualify if…
You likely don't qualify if…
You would receive injections of immune therapy medications directly into your lung tumor (guided by imaging), possibly combined with chemotherapy or other drugs, over several weeks before your scheduled surgery. Your doctors will monitor you closely with blood tests and imaging scans to see how your tumor responds. After the neoadjuvant (pre-surgery) treatment, you will have surgery to remove the cancer, and then you'll be followed for safety and how well the treatment worked.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
China